TLDR
- PepsiCo stock slips as weak snack demand pressures quarterly results.
- GLP-1 drug adoption continues reshaping snack buying habits nationwide.
- North American beverage sales trail Coca-Cola’s stronger regional growth.
- Price cuts fail to revive demand for Lay’s, Doritos, and Cheetos.
- PepsiCo faces pressure to innovate as healthier eating gains momentum.
PepsiCo, Inc. (PEP) shares fell 1.56% to $136.33 after weaker North American snack demand pressured quarterly performance. The company reported softer food sales despite earlier price reductions across several flagship brands. Meanwhile, changing consumer habits and wider GLP-1 drug adoption continued to weigh on its growth outlook.
North American Snack Business Faces Fresh Pressure
PepsiCo reported a 2% sales decline in its North American food business during the second quarter ended June 13. However, food volumes remained flat despite earlier price cuts on brands including Lay’s, Doritos, Cheetos, and Tostitos. Consequently, the results showed that lower prices failed to generate stronger demand.
The latest performance reversed the modest improvement recorded during the first quarter. Earlier, the company posted about 2% volume growth as its North American food business returned to growth. However, food volumes have now declined in four of the past six quarters.
PepsiCo’s beverage division also faced weaker demand across North America during the quarter. Beverage volumes declined 4%, while Coca-Cola previously reported 4% regional volume growth. As a result, PepsiCo continued losing momentum against its largest beverage competitor.
Health Trends and GLP-1 Drugs Reshape Consumer Demand
Consumers continue shifting toward products with stronger nutritional value and functional health benefits. Many households now prefer foods containing higher protein, lower sugar, and added fiber. Traditional salty snacks and sweet treats face slower demand across the market.
GLP-1 weight-loss drugs have accelerated that change during the past year. According to PwC analysis using Numerator data, 21% of U.S. households used GLP-1 drugs in May 2026. That figure increased sharply from 9% reported during January 2025.
Users of those medications generally purchase fewer sugary products and consume fewer salty snacks. PepsiCo faces additional pressure because food brands generate approximately 58% of its annual revenue. Besides, slower snack consumption directly affects one of the company’s largest revenue sources.
Company Response and Growth Challenges Continue
PepsiCo acknowledged that recovery across its North American operations may take longer than previously expected. The company continues adjusting pricing strategies while expanding products that match changing consumer preferences. Faster product innovation remains essential as consumer trends evolve more quickly.
The latest results also increase pressure on PepsiCo to strengthen its overall business performance. Elliott Investment Management disclosed an approximately $4 billion stake nearly ten months ago. Since then, the firm has encouraged stronger beverage performance and consideration of non-core food asset sales.
PepsiCo shares have declined about 4% this year, while Coca-Cola stock has gained more than 20%. Meanwhile, higher living costs continue encouraging shoppers to prioritize essential purchases and healthier food choices. Therefore, PepsiCo must balance affordability, innovation, and changing consumer preferences to restore stronger sales momentum.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
